查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2134984

2026年癌症藥物研發管線逐公司分析

Oncology Drug Pipeline Analysis by Company, 2026
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 142 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

腫瘤學仍然是製藥和生物技術行業中規模最大、最具活力的治療領域，在全球臨床開發活動中佔據相當大的比例。免疫療法、標靶治療、抗體藥物複合體（ADC）、細胞療法、基因療法、放射性藥物、癌症疫苗和雙特異性抗體等新型療法的出現，大大拓展了腫瘤藥物研發的前景。隨著製藥公司致力於滿足多種癌症適應症的未滿足需求，全面的研發管線分析變得日益重要。

藥物研發管線分析能夠提供關於臨床實驗療法、臨床試驗進展、技術平台、競爭對手定位、授權機會、監管趨勢和未來市場潛力的關鍵資訊。製藥公司、生技公司、投資者、合約研究組織 (CRO) 和醫療保健相關人員越來越依賴研發管線資訊來識別成長機會、評估競爭威脅、最佳化投資組合策略並支持投資決策。隨著腫瘤領域的創新日益複雜，對先進分析工具和策略性研發管線評估服務的需求也持續成長。

市場促進因素

全球癌症發生率不斷上升

  • 市場成長的主要促進因素之一是全球癌症發生率的上升。人口老化、生活方式相關的風險因素、環境暴露以及診斷能力的提高，都持續導致已開發經濟體和新興經濟體癌症發生率的上升。
  • 疾病負擔日益加重，推動了對癌症研究的大量投資，導致進入臨床開發的臨床實驗療法數量增加，也使得對研發管線分析的需求更加迫切。

擴大癌症領域的研究和開發

  • 腫瘤學領域始終佔據全球藥物研發投資的最大佔有率。各公司正積極研發針對多種癌症適應症的治療方法，進而形成競爭激烈且快速發展的藥物研發環境。
  • 隨著臨床階段資產和新興技術的不斷增加，對詳細的研發管線資訊和競爭性基準測試解決方案的需求也日益成長。

精準醫療的發展

  • 精準腫瘤學正透過基因組分析、生物標記檢測、分子診斷和個人化治療方案，革新癌症治療。隨著製藥公司日益專注於針對特定基因型患者群體的標靶治療，研發管線的複雜性也不斷增加。
  • 各組織需要先進的分析能力來評估新療法、識別市場機會並監測精準醫療生態系統中的技術進步。

對策略決策日益成長的需求

  • 在生命科學產業，產品線分析已成為策略規劃的重要組成部分。各公司正在利用產品線資訊來支援許可決策、併購評估、夥伴關係建立、產品組合最佳化和打入市場策略。
  • 腫瘤領域對數據驅動決策的需求日益成長，正在加速管道分析服務和平台的採用。

市場限制因素

快速變化的競爭格局

  • 腫瘤市場瞬息萬變，新療法不斷進入臨床研發階段，法律規範也持續改變。要維持研發管線資訊的準確性和時效性，需要持續的監控和大量的分析資源。
  • 隨著創新步伐加快，長期預測和競爭分析變得越來越具有挑戰性。

數據複雜性和碎片化

  • 腫瘤研發管線資訊分散在多個資訊來源中，包括臨床試驗註冊資料庫、科學論文、監管資料庫、會議報告、公司資訊披露和醫療保健資料集。
  • 整合和解釋大量異質資料會帶來分析上的挑戰，並增加研究成本。

監理不確定性

  • 藥物研發計畫受到不斷變化的監管要求、不斷演變的臨床終點以及波動不定的醫保報銷預期的影響。這些因素會影響研發管線的評估、研發進度和商業性潛力。
  • 監管方面的不確定性可能會使管道評估和投資決策變得複雜。

目錄

第1章：引言

  • 調查方法
  • 調查範圍
    • 分析：按公司
    • 分析：按發展階段
    • 分析：按干預類型分類
    • 分析：按臨床試驗狀態
    • 分析：按地區
  • 數據來源和檢驗
  • 定義和假設

第2章 疾病概述

  • 癌症分類
  • 癌症的主要類型
  • 症狀和臨床觀察
  • 診斷
  • 目前治療狀況
  • 流行病學和疾病負擔
  • 未滿足的臨床需求

第3章執行摘要

  • 臨床階段產品線概覽
  • 按開發階段分類的管道分佈
  • 臨床試驗活動中的主要公司
  • 主要臨床實驗藥物和療法
  • 各地區臨床試驗現狀
  • 管道構建中的關鍵趨勢和發現

第4章：腫瘤藥物研發管線的發展趨勢

  • 促進因素
  • 抑制因子
  • 潛在機會

第5章 管道分析/預測

  • 管道分析：按公司分類
    • Roche
    • Merck & Co.
    • Bristol Myers Squibb
    • AstraZeneca
    • Pfizer
    • Novartis
    • Johnson & Johnson Innovative Medicine
    • Gilead Sciences
    • Eli Lilly and Company
    • Amgen
  • 管線分析：依開發階段分類
    • 第一階段
    • 第一階段
    • 第一/二期
    • 第二階段
    • 第二/三期
    • 第三階段
  • 管道分析：依干預類型分類
    • 製藥
    • 生物
    • 基因
  • 研發管線分析：依臨床試驗狀態分類
    • 我們尚未開始招募參與者。
    • 招募測試對象
    • 目前已暫停招募參與者。
    • 完成
    • 取消/撤回/暫停
  • 管道分析：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 臨床試驗和病患分析
    • 按註冊患者人數統計的臨床試驗
    • 依研究設計進行的臨床試驗
    • 患者年齡要求
    • 關於患者性別的合格標準
  • 贊助和合作關係分析
    • 主要商業贊助商
    • 主要學術和研究贊助商
    • 主要合作夥伴組織
    • 對贊助商和合作研究機構的分析
  • 近期和未來管道趨勢
    • 近期啟動的臨床試驗
    • 目前正在招募受試者的臨床試驗
    • 近期完成的臨床試驗
    • 後期臨床試驗即將完成
    • 近期已發表結果的臨床試驗

第6章：公司簡介

  • Roche
  • Merck & Co.
  • Bristol Myers Squibb
  • AstraZeneca
  • Pfizer
  • Novartis
  • Johnson & Johnson Innovative Medicine
  • Gilead Sciences
  • Eli Lilly and Company
  • Amgen

第7章 圖表清單

第8章：圖表清單

簡介目錄
Product Code: KSI-008852

Oncology remains the largest and most dynamic therapeutic area within the pharmaceutical and biotechnology industries, accounting for a substantial proportion of global clinical development activity. The continuous emergence of novel treatment modalities-including immunotherapies, targeted therapies, antibody-drug conjugates (ADCs), cell therapies, gene therapies, radiopharmaceuticals, cancer vaccines, and bispecific antibodies-has significantly expanded the oncology drug development landscape. As pharmaceutical companies seek to address unmet medical needs across multiple cancer indications, the importance of comprehensive pipeline analysis has increased substantially.

Drug pipeline analysis provides critical insights into investigational therapies, clinical trial progress, technology platforms, competitive positioning, licensing opportunities, regulatory developments, and future market potential. Pharmaceutical companies, biotechnology firms, investors, contract research organizations, and healthcare stakeholders increasingly rely on pipeline intelligence to identify growth opportunities, assess competitive threats, optimize portfolio strategies, and support investment decisions. The growing complexity of oncology innovation continues to drive demand for advanced analytical tools and strategic pipeline assessment services.

Market Drivers

Rising Global Cancer Incidence

  • One of the primary drivers of market growth is the increasing prevalence of cancer worldwide. Aging populations, lifestyle-related risk factors, environmental exposures, and improved diagnostic capabilities continue to contribute to rising cancer incidence across both developed and emerging economies.
  • The growing disease burden is encouraging substantial investment in oncology research, leading to a larger number of investigational therapies entering clinical development and expanding the need for pipeline analysis.

Expansion of Oncology Research and Development

  • Oncology consistently attracts the highest levels of pharmaceutical research investment globally. Companies are actively developing therapies across a broad spectrum of cancer indications, resulting in a highly competitive and rapidly evolving drug development environment.
  • The growing number of clinical-stage assets and emerging technologies has increased demand for detailed pipeline intelligence and competitive benchmarking solutions.

Growth of Precision Medicine

  • Precision oncology is transforming cancer treatment through the use of genomic profiling, biomarker testing, molecular diagnostics, and personalized therapeutic approaches. As drug developers increasingly focus on targeted therapies for genetically defined patient populations, pipeline complexity continues to increase.
  • Organizations require sophisticated analytical capabilities to evaluate emerging therapies, identify market opportunities, and monitor technological advancements within the precision medicine ecosystem.

Increasing Strategic Decision-Making Requirements

  • Pipeline analysis has become an essential component of strategic planning within the life sciences industry. Companies use pipeline intelligence to support licensing decisions, merger and acquisition evaluations, partnership development, portfolio optimization, and market entry strategies.
  • The growing need for data-driven decision-making is accelerating adoption of oncology pipeline analysis services and platforms.

Market Restraints

Rapidly Evolving Competitive Landscape

  • The oncology market evolves rapidly as new therapies enter clinical development and regulatory pathways continue to change. Maintaining accurate and up-to-date pipeline intelligence requires continuous monitoring and significant analytical resources.
  • The pace of innovation can make long-term forecasting and competitive assessment increasingly challenging.

Data Complexity and Fragmentation

  • Oncology pipeline information is distributed across multiple sources, including clinical trial registries, scientific publications, regulatory databases, conference presentations, corporate disclosures, and healthcare datasets.
  • Integrating and interpreting large volumes of heterogeneous data can create analytical challenges and increase research costs.

Regulatory Uncertainty

  • Drug development programs are subject to changing regulatory requirements, evolving clinical endpoints, and shifting reimbursement expectations. These factors can influence pipeline valuations, development timelines, and commercial potential.
  • Regulatory uncertainty may complicate pipeline assessments and investment decisions.

Technology and Segment Insights

  • The global oncology drug pipeline analysis market can be segmented by therapy modality, development stage, cancer indication, technology platform, application, end user, and geography.
  • By therapy modality, the market includes immunotherapies, targeted therapies, antibody-drug conjugates, cell therapies, gene therapies, radiopharmaceuticals, cancer vaccines, bispecific antibodies, small-molecule therapies, and combination therapies. Immunotherapies continue to account for a substantial portion of pipeline activity due to their demonstrated clinical success across multiple cancer indications.
  • Targeted therapies also represent a major segment as pharmaceutical companies increasingly develop biomarker-driven treatments designed for specific molecular abnormalities and patient populations.
  • By development stage, the market includes discovery-stage programs, preclinical candidates, Phase I trials, Phase II trials, Phase III trials, regulatory-stage assets, and approved products undergoing lifecycle expansion. Early-stage and mid-stage development programs represent significant areas of analysis because they often provide insight into future competitive landscapes and emerging treatment trends.
  • By cancer indication, the market includes lung cancer, breast cancer, colorectal cancer, prostate cancer, hematologic malignancies, gastric cancer, liver cancer, pancreatic cancer, ovarian cancer, melanoma, brain tumors, and other oncology indications. Lung and breast cancer continue to dominate pipeline activity due to their large patient populations, extensive research investments, and ongoing therapeutic innovation.
  • By technology platform, the market includes monoclonal antibodies, antibody-drug conjugates, CAR-T therapies, T-cell receptor therapies, RNA-based therapeutics, gene editing technologies, oncolytic viruses, protein degradation technologies, and next-generation immunotherapy platforms. Emerging technology platforms are attracting increasing attention as developers seek novel approaches to address treatment resistance and improve clinical outcomes.
  • By application, the market includes competitive intelligence, portfolio assessment, investment analysis, licensing evaluation, merger and acquisition support, strategic planning, market forecasting, and regulatory monitoring. Competitive intelligence and portfolio optimization represent major application areas due to the highly competitive nature of oncology drug development.
  • By end user, the market serves pharmaceutical companies, biotechnology firms, venture capital investors, private equity organizations, contract research organizations, consulting firms, academic institutions, and healthcare intelligence providers. Pharmaceutical and biotechnology companies account for the largest share of market demand because of their direct involvement in oncology drug development and commercialization.
  • Technological advancements are transforming pipeline analysis through artificial intelligence, machine learning, natural language processing, predictive analytics, knowledge graphs, and real-world evidence platforms. These technologies improve the identification of emerging trends, assessment of competitive threats, and forecasting of clinical and commercial outcomes.
  • The increasing integration of genomic data, biomarker information, clinical trial results, scientific publications, and regulatory intelligence is enabling more comprehensive and actionable pipeline assessments. Advanced analytics platforms are helping organizations evaluate large datasets more efficiently and identify promising investment opportunities earlier in the development process.
  • Geographically, North America dominates the market due to its concentration of pharmaceutical companies, biotechnology innovators, academic research institutions, and venture capital investment activity. The United States remains the largest center for oncology drug development globally. Europe maintains a strong market position supported by extensive research infrastructure, regulatory expertise, and collaborative innovation networks. Asia-Pacific is expected to experience rapid growth due to expanding biotechnology ecosystems, increasing oncology research investments, rising clinical trial activity, and growing pharmaceutical innovation in countries such as China, Japan, South Korea, and India.

Competitive and Strategic Outlook

  • The competitive landscape is characterized by healthcare intelligence providers, pharmaceutical consulting firms, biotechnology analytics companies, market research organizations, and specialized competitive intelligence providers. Organizations compete based on data quality, analytical depth, therapeutic expertise, technology capabilities, and the ability to deliver actionable strategic insights.
  • Companies are increasingly investing in artificial intelligence-driven analytics platforms, real-time data monitoring systems, and integrated intelligence solutions to improve pipeline visibility and forecasting accuracy. Strategic collaborations between analytics providers, pharmaceutical companies, and research organizations are becoming increasingly common as stakeholders seek to enhance decision-making capabilities and improve competitive positioning.
  • The growing importance of precision oncology, targeted therapies, immuno-oncology, and advanced biologics is expected to further increase demand for specialized pipeline analysis services. Organizations that can effectively combine scientific expertise with advanced analytical technologies are likely to gain significant competitive advantages within the evolving oncology intelligence market.

Conclusion

  • The global oncology drug pipeline analysis market is positioned for strong growth through 2031, supported by increasing cancer prevalence, expanding oncology research investments, rapid therapeutic innovation, and growing demand for strategic intelligence. As oncology drug development becomes more complex and competitive, comprehensive pipeline analysis is becoming an essential tool for pharmaceutical companies, biotechnology firms, investors, and healthcare stakeholders. Although challenges related to data complexity, competitive dynamics, and regulatory uncertainty remain, advances in artificial intelligence, predictive analytics, and precision medicine are expected to significantly enhance the value and impact of oncology pipeline intelligence over the coming years.

Key Benefits of this Report

  • Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
  • Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
  • Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
  • Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
  • Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

  • Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

  • Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
  • Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
  • Competitive positioning, strategies, and market share evaluation, and trade analysis
  • Revenue growth and forecast assessment across segments and regions
  • Company profiling including strategies, products, financials, and key developments.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Research Methodology
  • 1.2. Research Scope
    • 1.2.1. Analysis by Company
    • 1.2.2. Analysis by Development Phase
    • 1.2.3. Analysis by Intervention Type
    • 1.2.4. Analysis by Clinical Trial Status
    • 1.2.5. Analysis by Geography
  • 1.3. Data Sources and Validation
  • 1.4. Definitions and Assumptions

2. DISEASE OVERVIEW

  • 2.1. Introduction
  • 2.2. Cancer Classification
  • 2.3. Major Cancer Types
  • 2.4. Symptoms and Clinical Manifestations
  • 2.5. Diagnosis
  • 2.6. Current Treatment Landscape
  • 2.7. Epidemiology and Disease Burden
  • 2.8. Unmet Clinical Needs

3. EXECUTIVE SUMMARY

  • 3.1. Clinical-Stage Pipeline Overview
  • 3.2. Pipeline Distribution by Development Phase
  • 3.3. Leading Companies by Clinical Trial Activity
  • 3.4. Leading Investigational Drugs and Interventions
  • 3.5. Geographic Clinical Trial Landscape
  • 3.6. Key Pipeline Trends and Findings

4. ONCOLOGY PIPELINE DYNAMICS

  • 4.1. Drivers
  • 4.2. Restraints
  • 4.3. Pipeline Opportunities

5. PIPELINE ANALYSIS / OUTLOOK

  • 5.1. PIPELINE ANALYSIS BY COMPANY
    • 5.1.1. Roche
    • 5.1.2. Merck & Co.
    • 5.1.3. Bristol Myers Squibb
    • 5.1.4. AstraZeneca
    • 5.1.5. Pfizer
    • 5.1.6. Novartis
    • 5.1.7. Johnson & Johnson Innovative Medicine
    • 5.1.8. Gilead Sciences
    • 5.1.9. Eli Lilly and Company
    • 5.1.10. Amgen
  • 5.2. PIPELINE ANALYSIS BY DEVELOPMENT PHASE
    • 5.2.1. Early Phase I
    • 5.2.2. Phase I
    • 5.2.3. Phase I/II
    • 5.2.4. Phase II
    • 5.2.5. Phase II/III
    • 5.2.6. Phase III
  • 5.3. PIPELINE ANALYSIS BY INTERVENTION TYPE
    • 5.3.1. Drug
    • 5.3.2. Biological
    • 5.3.3. Genetic
  • 5.4. PIPELINE ANALYSIS BY CLINICAL TRIAL STATUS
    • 5.4.1. Not Yet Recruiting
    • 5.4.2. Recruiting
    • 5.4.3. Active, Not Recruiting
    • 5.4.4. Completed
    • 5.4.5. Terminated / Withdrawn / Suspended
  • 5.5. PIPELINE ANALYSIS BY GEOGRAPHY
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia-Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa
  • 5.6. CLINICAL TRIAL AND PATIENT ANALYSIS
    • 5.6.1. Clinical Trials by Patient Enrollment
    • 5.6.2. Clinical Trials by Study Design
    • 5.6.3. Patient Age Eligibility
    • 5.6.4. Patient Sex Eligibility
  • 5.7. SPONSOR AND COLLABORATION ANALYSIS
    • 5.7.1. Leading Commercial Sponsors
    • 5.7.2. Leading Academic and Research Sponsors
    • 5.7.3. Leading Collaborating Organizations
    • 5.7.4. Sponsor-Collaborator Analysis
  • 5.8. RECENT AND UPCOMING PIPELINE ACTIVITY
    • 5.8.1. Recently Initiated Clinical Trials
    • 5.8.2. Newly Recruiting Clinical Trials
    • 5.8.3. Recently Completed Clinical Trials
    • 5.8.4. Late-Stage Trials Approaching Primary Completion
    • 5.8.5. Trials with Recently Posted Results

6. COMPANY PROFILES

  • 6.1. Roche
  • 6.2. Merck & Co.
  • 6.3. Bristol Myers Squibb
  • 6.4. AstraZeneca
  • 6.5. Pfizer
  • 6.6. Novartis
  • 6.7. Johnson & Johnson Innovative Medicine
  • 6.8. Gilead Sciences
  • 6.9. Eli Lilly and Company
  • 6.10. Amgen

7. LIST OF TABLES

8. LIST OF FIGURES